Jefferies analyst Chris Howerton downgraded MEI Pharma to Underperform from Hold with a price target of 10c, down from 40c, citing what the firm views as an unfavorable risk-reward given sector sentiment and capital risk.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly